Hui Xu1, Yan-Long Liu, Yan-Mei Yang, Xin-Shu Dong. 1. Department of Oncosurgery, The Affiliated 4th Hospital of Harbin Medical University, 37 Yiyuan Street, Nangang District, Harbin, 150001, People's Republic of China.
Abstract
PURPOSE: Increasing experimental evidences suggest that ubiquitin-specific protease 22 (USP22), a cancer stem cell marker, plays a crucial role in pathological processes of epithelial malignancies and other solid tumors, which makes it a potential target for cancer therapy. The aim of this study was to study the roles of USP22 in human colorectal cancer cell line HCT116 by suppressing USP22 expression with micro-interfering RNA (miRNA). METHODS: With the knock-down of USP22, the changes of cellular proliferation, cell cycle, cell apoptosis, and major vault protein (MVP) expression were investigated. Furthermore, a tumor xenograft model in nude mice was injected with USP22 miRNA silencing vector and the immunohistochemical staining was performed to evaluate the USP22 expression in the tumor. RESULTS: The knock-down of USP22 protein expression by miRNA resulted in the inhibition of cellular proliferation, the accumulation of cells in the G1 phase, the reduction of apoptosis, and the down-regulation of MVP expression. Furthermore, with orthotopic mice as a model, tumor growth was suppressed when USP22 miRNA silencing vector was injected. Immunohistochemical analyses of tumor sections revealed that USP22 expression in animals decreased when USP22 expression was inhibited by miRNA. CONCLUSION: These results support the hypothesis that USP22 plays a crucial role in tumor formation and growth by regulating cell proliferation with USP22-dependent signaling pathway. Furthermore, USP22 acts as a major transcriptional factor to regulate MVP drug resistant gene. Taken together, targeting USP22 may offer additional possibilities in cancer therapy.
PURPOSE: Increasing experimental evidences suggest that ubiquitin-specific protease 22 (USP22), a cancer stem cell marker, plays a crucial role in pathological processes of epithelial malignancies and other solid tumors, which makes it a potential target for cancer therapy. The aim of this study was to study the roles of USP22 in humancolorectal cancer cell line HCT116 by suppressing USP22 expression with micro-interfering RNA (miRNA). METHODS: With the knock-down of USP22, the changes of cellular proliferation, cell cycle, cell apoptosis, and major vault protein (MVP) expression were investigated. Furthermore, a tumor xenograft model in nude mice was injected with USP22 miRNA silencing vector and the immunohistochemical staining was performed to evaluate the USP22 expression in the tumor. RESULTS: The knock-down of USP22 protein expression by miRNA resulted in the inhibition of cellular proliferation, the accumulation of cells in the G1 phase, the reduction of apoptosis, and the down-regulation of MVP expression. Furthermore, with orthotopic mice as a model, tumor growth was suppressed when USP22 miRNA silencing vector was injected. Immunohistochemical analyses of tumor sections revealed that USP22 expression in animals decreased when USP22 expression was inhibited by miRNA. CONCLUSION: These results support the hypothesis that USP22 plays a crucial role in tumor formation and growth by regulating cell proliferation with USP22-dependent signaling pathway. Furthermore, USP22 acts as a major transcriptional factor to regulate MVP drug resistant gene. Taken together, targeting USP22 may offer additional possibilities in cancer therapy.
Authors: Yue Zhao; Guillaume Lang; Saya Ito; Jacques Bonnet; Eric Metzger; Shun Sawatsubashi; Eriko Suzuki; Xavier Le Guezennec; Hendrik G Stunnenberg; Aleksey Krasnov; Sofia G Georgieva; Roland Schüle; Ken-Ichi Takeyama; Shigeaki Kato; László Tora; Didier Devys Journal: Mol Cell Date: 2008-01-18 Impact factor: 17.970
Authors: M Kitazono; T Sumizawa; Y Takebayashi; Z S Chen; T Furukawa; S Nagayama; A Tani; S Takao; T Aikou; S Akiyama Journal: J Natl Cancer Inst Date: 1999-10-06 Impact factor: 13.506
Authors: G L Scheffer; P L Wijngaard; M J Flens; M A Izquierdo; M L Slovak; H M Pinedo; C J Meijer; H C Clevers; R J Scheper Journal: Nat Med Date: 1995-06 Impact factor: 53.440
Authors: M A Izquierdo; R H Shoemaker; M J Flens; G L Scheffer; L Wu; T R Prather; R J Scheper Journal: Int J Cancer Date: 1996-01-17 Impact factor: 7.396
Authors: M A Izquierdo; A G van der Zee; J B Vermorken; P van der Valk; J A Beliën; G Giaccone; G L Scheffer; M J Flens; H M Pinedo; P Kenemans Journal: J Natl Cancer Inst Date: 1995-08-16 Impact factor: 13.506
Authors: D Schadendorf; A Makki; C Stahr; A van Dyck; R Wanner; G L Scheffer; M J Flens; R Scheper; B M Henz Journal: Am J Pathol Date: 1995-12 Impact factor: 4.307